Dapagliflozin for the treatment of heart failure with reduced ejection fraction in Brazil: a cost-effectiveness analysisResearch in context
Summary: Background: Heart failure, a complex clinical syndrome with high morbidity and mortality, has become a significant burden on public health. Recently, a new class of antidiabetic agents–the sodium-glucose cotransporter 2 (SGLT2) inhibitors–was associated with a significant reduction on mort...
Saved in:
Main Authors: | Marcio Coutinho Xavier Naves, Angelica Amorim Amato, Ivan Ricardo Zimmermann, Henry Maia Peixoto |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | The Lancet Regional Health. Americas |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2667193X24002953 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration
by: Marwa M. Saeed
Published: (2024-12-01) -
Combination of dapagliflozin and pioglitazone lacks superiority against monotherapy in streptozotocin-induced nephropathy
by: Aneta Cinakova, et al.
Published: (2025-01-01) -
Animal experiments and network pharmacology to explore the anti-inflammatory mechanism of dapagliflozin in the treatment of polycystic ovary syndrome
by: Yong Liu, et al.
Published: (2025-12-01) -
Repurposing Dapagliflozin for Mitigation of the Kidney Injury Triggered by Cadmium in Rats: Role of Autophagy, Apoptosis, and the SIRT1/Nrf2/HO-1 Pathway
by: Hany H. Arab, et al.
Published: (2024-12-01) -
Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction
by: Hong-xia Ma, et al.
Published: (2024-12-01)